Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Demand & Sales Volume by Product & Devices The global veterinary pain management market will witness a robust CAGR of 8.12%, valued at $1.44 billion in 2021, expected to appreciate and reach $2.92 billion by 2030, confirms Strategic Market Research. The North American region led the industry in 2020 with a burgeoning CAGR. In the overall veterinary practice, pain management provides veterinary practitioners with the necessary information required to detect and manage pain in a plethora of animal species. In canine and feline medicine, pain control is an important part of compassionate care. Nursing care, nondrug approaches (such as bandaging, cold packs or heat, physical therapy), and drug therapies are necessary when dealing with stressed or painful animals. Types of Pain - Pain Serves a Protective Role that Alerts an Individual to Injury from the Environment or Within. Acute pain: It is a sharp, throbbing, aching, or burning sensation. It's a predictable, visible reaction to unpleasant stimuli (such as twisting, crushing, or scorching) or tissue injury (such as wounds, bruises, and surgical incisions). Acute pain might take anywhere from three days to three months to heal. Chronic pain: Pain signals remain active in the nervous system for more than three months. According to American Animal Hospital Association, Chronic pain is frequent in companion animals, with Osteoarthritis being the most common cause. The prevalence of Osteoarthritis is close to 40% in dogs and more than 50% in cats. Chronic pain is difficult to treat since standard analgesics like non-steroidal anti-inflammatory medications (NSAIDs) and opioids are typically less ineffective. Cancer pain: Acute pain (due to primary tumor development, a spreading malignant condition, or the toxic effects of radiation or chemotherapy) and chronic pain (secondary tumor growth, spreading cancerous disease, and toxic effects of chemotherapy or radiation) are all possible causes. According to the Animal Care Foundation, estimates indicate that there are 65 million dogs and 32 million cats in the United States. Roughly 12 million new cancer diagnoses are made in cats and dogs each year. Neuropathic Pain - It Is Caused by Damage to A Nerve or Part of The Central Nervous System. This Type of Pain Is Rarely Diagnosed Due to The Inability to Communicate a Problem. Types of Drugs: The four classes of injectable drugs are: Opioid analgesics: Opioids work on nervous system pain receptors in the brain and spinal cord for pain relief. (butorphanol and buprenorphine) Non-steroidal anti-inflammatory drugs (NSAID) analgesics: NSAIDs work directly on the areas of inflammation and injury found in the body's tissues (carprofen, meloxicam) Dissociative anesthetic/sedatives: Dissociative effects result in feelings of drowsiness, slow ineffective breathing, respiratory depression, relief of pain, increased pulse rate, amnesia along with loss of muscle control. It also leads to cognitive and memory impairment. (ketamine, tiletamine) Local/regional anesthetics: Local anesthesia numbs just a small area of tissue where a minor procedure is to be done (lidocaine, bupivacaine, proparacaine). Drivers - High Adoption of Diagnostic Tools, Rising Pet Ownership, Innovations in Vaccines and Diagnosis, Surge in Pet Insurance, and Increasing Pet Disease High adoption of Diagnostic tools: MRI (Magnetic Resonance Imaging), laser therapy, 3D printing, radiology, endoscopy, ultrasound scans, and laparoscopy used solely on human beings are now the new normal for treating pets and other animals well. Rising Pet Ownership: Pets expand opportunities to exercise, socialize, play and go for walks regularly to help lower blood pressure, cholesterol, and triglyceride levels. Companionship from pets helps to cope with loneliness and sadness, due to which there is a sharp increase in pet ownership. According to the National Pet Owners Survey (2022) conducted by the American Pet Products Association (APPA), Pet ownership in the US household increased from 56% in 1988 to 70% (90.5 million families) in 2021. Innovations in Vaccines and diagnosis: Innovations in vaccine development like mRNA Vaccines, the Precision system for vaccine delivery, heat resistant Vaccines, and customized vaccines are gaining attention. Diagnostic Innovation through Artificial intelligence, Microfluidics, Molecular diagnostics, and other user-friendly tools are potential game-changers for the growth of the animal health industry. A surge in Pet insurance: Insurance products primarily covering cases of death due to disease or accidents, which includes natural calamities and deadly injuries caused by other animals, are on the rise. As per the North American Pet Health Insurance Association (NAPHIA), the total premium volume for pet insurance in the US was nearly $2.6 billion for 3.9 million pets (a 28% annual increase). Dogs (82%) and cats (18%) are the most insured pets. Technological advancements: Advancements in digital monitoring and surveillance rapidly transform the animal health landscape, improving speed and efficiency. Digital technologies Products like smart tags, sensors, remote monitoring surveillance, and smart building designs are becoming highly significant. Rising pet disease: Both dogs and cats have a high treatment cost due to health problems due to common diseases, including epizootic disease (nonhuman animal disease epidemics). According to Pet Life Today, dogs and cats have high treatment expenditures due to health problems. For dogs, skin allergies cost ($600-$1100), ear infections ($13-$40), non-cancerous skin mass, skin infections ($20), and arthritis ($200-$2500) are more common. However, cats face bladder/urinary tract disease the treatment of which costs ($150-$600), dental disease ($300-$1300), chronic kidney disease, vomiting, and excessive thyroid hormone ($700). Restraints - Side Effects and High cCst Side-effects: The digestive tract, kidneys, and liver are the most common sites where NSAIDs cause side effects. Vomiting, loss of appetite, decreased activity level, and diarrhea is some of the most common NSAID side effects in animals reported to the FDA's Center for Veterinary Medicine. Stomach and intestinal ulcers/perforations (holes), renal failure, liver failure, and death are some of the other severe effects. High cost: Annual cost of owning a pet is high as pet food and veterinary services are the two leading sources of spending. According to National Pet Owners Survey (2022), Basic Annual Expenses for Dogs and Cats were $1480 and $902, respectively, including food, supplies, over-the-counter medicine, veterinary care, live animal purchases, and grooming and boarding. Opportunities Emerging Treatment Modalities: There is increased popularity of nonconventional and non-pharmaceutical treatment modalities. Nonconventional modalities include acupuncture, homeopathic remedies, Healing Touch, qigong, and Reiki. While non-pharmaceutical treatment modalities include physical therapy, chiropractic, acupuncture, psychotherapy, massage, educational classes, or exercise. Alternatives to Antibiotics: These products target bacteria and cure bacterial infections similar to Bacteriophages, cold ambient plasmas, Antimicrobial peptides, Nanotechnology treatments, and immunotherapies. Increasing Pet healthcare investments: High disposable income of pet owners and a strong human-animal bond increase the investment expenditure. The American Pet Products Association (APPA) study reveals that the US Pet Industry Expenditures increased from $53.3 billion (2012) to $123.6 billion (2021), including food, medicine, veterinary care, toys, grooming, and boarding. Parasite Control: There is an increasing urgency to discover new parasiticides like mRNA Parasite vaccines, Oral Parasiticides, Green Parasiticides, and other parasite control methods as warming temperatures due to climate change allow parasites to thrive in new regions. Nutritional Awareness: Growing understanding of the significance of diet, gut health, and natural disease immunity in animals opens new avenues for bettering animal health and welfare. Probiotics, Phytogenic feed additives, and novel feeds such as insect-based protein and seaweeds are opening opportunities for precision nutrition. The National Institutes of Health (NIH) announced spending $170 million over the next five years on the Nutrition for Precision Health (NPH) Program to advance the relatively new field of precision nutrition. Market Analysis Of Different Segments Covered in the Report Based on Products NSAIDs Anesthetics Opioids Other Drugs Based on Devices Laser Therapy Electromagnetic Therapy Based on Animal Type: Companion Livestock Based on Application: Osteoarthritis and Joint Pain Postoperative Pain Cancer Others Based on End-User: Hospitals and Clinics Retail Pharmacy Outlets Others Regional Coverage Analysis North America United States of America Canada Rest of North America Europe United Kingdom Germany Italy France Spain Russia Rest of Europe Asia-Pacific Australia China South Korea Japan Singapore India Rest of Asia-Pacific LAMEA Brazil Argentina Saudi Arabia United Arab Emirates South Africa Rest of LAMEA Segments Analysis & Insights By Product, the Non-steroidal Anti-inflammatory Drugs (NSAIDs) sector accounted for the biggest global veterinary pain management market share because medications are affordable, easier to administer, and cure a wider spectrum of disorders that causes pain on farm and companion animals. By Device Type, Laser Therapy is expected to have the largest industry share. Laser Therapy is highly effective, painless, non-invasive, and non-toxic which provides a better thermal response. It promotes tissue regeneration and repair, decreases inflammation, and returns cells to normal. By Application, the Osteoarthritis and Joint Pain category accounted for the biggest market share in terms of revenue. The number of Osteoarthritis and Joint Pain cases increases continuously, efficiently driving this segment's growth. By Animal type, the Companion Animal segment registered the largest industry share in terms of revenue due to the rising frequency of chronic diseases, increased awareness among animal healthcare organizations, growing pet population, and high animal healthcare spending in emerging nations. An increase in pet ownership, the need for effective animal care, and the rising prevalence of obesity and other chronic diseases such as Osteoarthritis and cancer are fuelling the market growth. As per the American Medical Veterinary Association, 77% of Veterinarians who work in private medical practices are Companion Animal Veterinarians. Reptiles, rabbits, ferrets, and other creatures can also be maintained as pets. By End User, Hospitals and Clinics lead the end-user segment due to the accessibility of a wide range of therapeutic and diagnostic options. Furthermore, an increase in the number of procedures and the demand for outpatient facilities are the key factors fostering the overall growth of this segment. According to the US Bureau of Labour Statistics (BLS), Veterinarians employed in the US are expected to increase from 89,200 in 2019 to 98,400 by 2029. The majority of veterinarians (76%) work in private clinics and hospitals, followed by self-employed veterinarians (14%) and government veterinarians (3%). North America leads the veterinary pain management market share because of the solid base of healthcare facilities, rising need for efficient animal care, steady rise in the number of pet owners, and rising research activities in this region. As per the report by American Veterinary Medical Association (AVMA) on the market for veterinary services, nearly 30,000 veterinary clinics in the US cater to companion animals, primarily cats and dogs. Furthermore, Asia-Pacific is predicted to remain veterinary pain management's fastest growing market due to increased government measures to promote awareness, a rise in medical tourism, growing research activities in the region, a rising pet population, and growing demand for better healthcare in the region. Veterinary Pain Management Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 1.44 Billion The revenue forecast in 2030 USD 2.92 Billion Growth rate CAGR of 8.12% The base year for estimation 2021 Historical data 2017 – 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Product, Device, Animal Type, Application, End-user, and Region. By Product NSAIDs, Anaesthetics, Opioids and Other Drugs By Devices Laser Therapy and Electromagnetic Therapy By Animal type Companion and Livestock By Application Osteoarthritis/Joint Pain, Postoperative Pain, Cancer, and Others By End-User Hospitals/Clinics, Retail Pharmacy Outlets, and Others By Region North America, Europe, Asia-Pacific, Latin America the Middle East, and Africa. Country Scope US, Mexico, Canada, Germany, UK, France, China, Japan, India, etc. Company Usability Profiles Charoen Pokphand Group, Sumitomo Chemical, Zoetis, Elanco, Dechra Pharmaceuticals, Bayer AG, Evonik Industries AG, Norbrook, Ceva, Assisi Animal Health, Merck Sharp & Dohme Corp, Medtronic Boehringer Ingelheim International GmbH, Virbac, Vetoquinol, DuPont, DSM, Adisseo, BASF SE, Novusint Cargill, ADM Nutreco, IDEXX Laboratories, and Kemin Industries Veterinary Pain Management Market Competitive Landscape Analysis The report defines the key competitors operating worldwide. The comparison is based on overall revenue generation, SWOT Analysis, Porter’s Five Force Analysis, market initiatives, veterinary pain management overview, R&D investment and expenditure, Import and export data, manufacturing aspects, value chain insights, industry share financials, global presence, production capacity, production sites and facilities, market potential, few among others. Zoetis Elanco Bayer AG Norbrook Ceva Dechra Pharmaceuticals Assisi Animal Health Merck Sharp & Dohme Corp BoehringerIngelheim International GmbH Virbac IDEXX Laboratories Vetoquinol Evonik Industries AG DuPont DSM Adisseo BASF SE ADM Nutreco Novusint Cargill Incorporated Charoen Pokphand Group) Sumitomo Chemical Kemin Industries, Inc. Medtronic Recent Developments In April 2022, the FDA approved Vatinoxan hydrochlorides and Medetomidine injection for dogs undergoing specific clinical examinations and procedures and minor surgical operations. Medetomidine is a synthetic drug used as a surgical anesthetic and an analgesic. Vatinoxan brings down the adverse cardiovascular effects of medetomidine by maintaining the heart rate in the normal range, thus improving the cardiovascular function and the safety profile of medetomidine while the dog is sedated. Zenalpha is aimed to provide sedation and relief of pain that lasts for the duration of the sedation to dogs for clinical examinations or procedures which require the dog to remain still, calm or quiet. In January 2022, the US FDA provided approval to Elanco Animal Health's Zorbium which is a (buprenorphine transdermal solution). Due to this approval, veterinarians now have another alternative for managing postoperative pain in cats, owing to this approval. Zorbium is the first and foremost transdermal buprenorphine animal drug targeted to control and relieve pain in cats post-surgery. Buprenorphine is classified as an opioid pain medication that acts on pain receptors in the central nervous system. A single treatment relieves the cat's suffering for four days. In January 2022, the FDA approved Solensia (frunevetmab injection), which is the first-ever drug to alleviate pain linked with arthritis in cats. It is the first monoclonal antibody (mAb) which is a new animal drug actively approved by the FDA for extensive usage in any animal species. Frunevetmab which is the active ingredient in Solensia is designed to recognize and attach to a protein called nerve growth factor (NGF), which is involved in regulating the pain to a great extent. When frunevetmab binds to NGF, it restricts the pain signal from reaching the brain. In August 2020, The WSAVA announced its partnership with animal health company Zoetis to improve pain management strategies. The partnership will support WSAVA's Global Pain Council, which aims to increase veterinary professionals' confidence and competence in companion animal pain management through initiatives such as its 'Teach the Teacher' training program and its Global Pain Guidelines. Global Pain Council comprises veterinary professionals worldwide with expertise in companion animal pain management that provides veterinary practices with educational resources and advice for effective pain management. Various Products that Key Market Leaders Develop: Product Function Key players ZORBIUM Controls the discomfort caused by surgical operations in cats. Elanco Carprieve Chewable Tablets for the relief of pain and inflammation associated with osteoarthritis in dogs Norbrook MELOXIDYL Used in adjunct treatments of joint inflammations. Ceva Assisi Loop Uses patented targeted pulsed electromagnetic field (tPEMF) technology to treat inflammation. Assisi Animal Health Frequently Asked Question About This Report What is the projected growth rate of the veterinary pain management market? The global veterinary pain management market size was $1.44 billion in 2021, and is predicted to reach $2.92 billion by 2030 at a CAGR of 8.12% during the forecast period of 2021 - 2030. How big is the Veterinary Pain Management market? The veterinary pain management market is expected to reach $1.44 billion in 2021, and is predicted to reach $ 2.92 billion by 2030. Name some of the veterinary medicine producers and manufacturers in Belgium? Top veterinary pharma companies like Panagro Health & Nutrition and Prodivet pharmaceuticals are specialized in the R&D of innovative veterinary products for livestock. Name some of the pivotal drugs in Veterinary Pain Management? The prevailing drugs in this segment are Acetaminophen, Amantadine, Bisphosphonates, Corticosteroids, Gabapentin, Maropitant, Opioids, and Polysulfated Glycosaminoglycans, Systemic Lidocaine and Tramadol. Also, while treatment, Local Anesthetics like Ketamine are used to reduce the sensations during Acute Pain of Canine DJD. Moreover, Feline DJD is very common in cats. Thus, Tricyclic antidepressants are used for chronic pain management in cats. What are some of the traditional and contemporary methods for Pain Management? Existing Segments like Homeopathy, Physical Rehabilitation, Hospice and Palliative Care, Chiropractic Care and Acupuncture for Pain Control are capturing market share. Also, Selective Serotonin (Norepinephrine) Reuptake Inhibitors, a class of medications that are effective in treating depression, are used. Weight optimization for pain management in chronic pain and Osteoarthritis are finding opportunities. Similarly, new fields like Nutrition Management for Pain Management and over the counter pain management for dogs are gaining momentum. What are the current trends in Global veterinary pain management Market? The Global veterinary pain management market forecast suggests that the market will grow to USD 2.92 Bn by 2030 with a healthy CAGR of 8.12%. North America is projected to remain veterinary pain managements Largest Market. 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Veterinary Pain Management Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Veterinary Pain Management Market 4.2.1 market, 2021 – 2030 (USD Million) 4.3 Regional Business Analysis 4.3.1 market, by region, 2021 - 2030 (USD Million) 4.4 By Product Business Analysis 4.4.1 market, By Product, 2021 - 2030 (USD Million) 4.5 By Devices Business Analysis 4.5.1 market, By Devices Type, 2021 - 2030 (USD Million) 4.6 By Animal Type Business Analysis 4.6.1 market, By Animal Type, 2021 - 2030 (USD Million) 4.7 By End-User Business Analysis 4.7.1 market, By End User, 2021 - 2030 (USD Million) 4.8 Application Business Analysis 4.8.1 market, By Application, 2021 - 2030 (USD Million) 4.9 Value Chain Analysis 4.10 Market Variable Analysis 4.10.1 Market Drivers Analysis 4.10.2 Market Restraints Analysis 4.11 Business Environment Analysis Tool 4.11.1 market PEST analysis 4.11.2 market Porter’s analysis 4.12 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Devices Analysis 5.11.1. Trends in Devices (2014-2021) 5.11.2. Trends in Devices (2021-2030) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By Region, By Country) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Manufacturing Sites, Area Served, Product 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Market: By Product Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. NSAIDs 7.3.1. NSAIDs market, 2021 - 2030 (USD Million) 7.4. Anaesthetics 7.4.1. Anaesthetics market, 2021 - 2030 (USD Million) 7.5 Opioids 7.5.1 Opioids market, 2021 - 2030 (USD Million) 7.6 Other Drugs 7.6.1 Other Drugs market, 2021 - 2030 (USD Million) 8. Market: By Devices Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Laser Therapy 8.3.1. Laser Therapy market, 2021 - 2030 (USD Million) 8.4. Electromagnetic Therapy 8.4.1. Electromagnetic Therapy market, 2021 - 2030 (USD Million) 9. Market: By Animal Type Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Companion 9.3.1. Companion Market, 2021 - 2030 (USD Million) 9.4. Livestock 9.4.1. Livestock market, 2021 - 2030 (USD Million) 10. Market: By End User Segment Analysis 10.1. Introduction 10.2. Sales Volume & Revenue Analysis (2021-2030) 10.3. Hospitals and Clinics 10.3.1. Hospitals and Clinics market, 2021 - 2030 (USD Million) 10.4. Retail Pharmacy Outlets 10.4.1. Retail Pharmacy Outlets market, 2021 - 2030 (USD Million) 10.5 Others 10.5.1 Others market, 2021 - 2030 (USD Million) 11. Market: By Application Segment Analysis 11.1. Introduction 11.2. Sales Volume & Revenue Analysis (2021-2030) 11.3. Osteoarthritis and Joint Pain 11.3.1. Osteoarthritis and Joint Pain market, 2021 - 2030 (USD Million) 11.4. Postoperative Pain 11.4.1. Postoperative Pain market, 2021 - 2030 (USD Million) 11.5 Cancer 11.5.1 Cancer market, 2021 - 2030 (USD Million) 11.6. Others 11.6.1. Others market, 2021 - 2030 (USD Million) 12. Market: Regional Outlook 12.1 North America 12.1.1. North America market, By End User, 2021 - 2030 (USD Million) 12.1.4. North America market, By Application, 2021 - 2030 (USD Million) 12.1.5. North America market, by Country, 2021 - 2030 (USD Million) 12.1.4.1. U.S. 12.1.4.1.1. U.S. market, By End User, 2021 - 2030 (USD Million) 12.1.4.2. Canada 12.1.4.2.1. Canada market, By End User, 2021 - 2030 (USD Million) 12.1.4.2.2. Canada market, By Region, 2021 - 2030 (USD Million) 12.1.4.2.3. Canada market, by Applications, 2021 - 2030 (USD Million) 12.2. Europe 12.2.1. Europe market, By End User, 2021 - 2030 (USD Million) 12.2.2. Europe market, By Application, 2021 - 2030 (USD Million) 12.2.5. Europe market, by country, 2021 - 2030 (USD Million) 12.2.4.1 U.K. 12.2.4.1.1. U.K. market, By End User, 2021 - 2030 (USD Million) 12.2.4.1.2. U.K. market, By Applications, 2021 - 2030 (USD Million) 12.2.4.1.3. U.K. market, by region, 2021 - 2030 (USD Million) 12.2.4.2. Germany 12.2.4.2.1. Germany market, By End User, 2021 - 2030 (USD Million) 12.2.4.2.2. Germany market, By Application, 2021 - 2030 (USD Million) 12.2.4.2.3. Germany market, by region, 2021 - 2030 (USD Million) 12.2.4.3. France 12.2.4.3.1. France market, By End User, 2021 - 2030 (USD Million) 12.2.4.3.2. France market, By Region, 2021 - 2030 (USD Million) 12.2.4.3.3. France market, by Application, 2021 - 2030 (USD Million) 12.2.4.4. Rest of Europe 12.2.4.4.1. Rest of Europe market, By End User, 2021 - 2030 (USD Million) 12.2.4.4.2. Rest of Europe market, By Region, 2021 - 2030 (USD Million) 12.2.4.4.3. Rest of Europe market, by Application, 2021 - 2030 (USD Million) 12.3. Asia Pacific 12.3.1. Asia Pacific market, By End User, 2021 - 2030 (USD Million) 12.3.2. Asia Pacific market, By Application, 2021 - 2030 (USD Million) 12.3.5. Asia Pacific market, by country, 2021 - 2030 (USD Million) 12.3.4.1. China 12.3.4.1.1. China market, By End User, 2021 - 2030 (USD Million) 12.3.4.1.2. China market, By Region, 2021 - 2030 (USD Million) 12.3.4.1.3. China market, by Application, 2021 - 2030 (USD Million) 12.3.4.2. India 12.3.4.2.1. India market, By End User, 2021 - 2030 (USD Million) 12.3.4.2.2. India market, By Region, 2021 - 2030 (USD Million) 12.3.4.2.3. India market, by Application, 2021 - 2030 (USD Million) 12.3.4.3. Japan 12.3.4.3.1. Japan market, By End User, 2021 - 2030 (USD Million) 12.3.4.3.3. Japan market, by Application, 2021 - 2030 (USD Million) 12.3.4.4. South Korea 12.3.4.4.1. South Korea market, By End User, 2021 - 2030 (USD Million) 12.3.4.4.3. South Korea market, by Application, 2021 - 2030 (USD Million) 12.3.4.5. Rest of ASIA PACIFIC 12.3.4.5.1. Rest of ASIA PACIFIC market, By End User 2021 - 2030 (USD Million) 12.3.4.5.3. Rest of ASIA PACIFIC market, by Application, 2021 - 2030 (USD Million) 12.4. Latin America 12.4.1. Latin America market, By End User, 2021 - 2030 (USD Million) 12.4.3. Latin America market, by Application, 2021 - 2030 (USD Million) 12.4.4. Latin America market, by country, 2021 - 2030 (USD Million) 12.4.4.1. Brazil 12.4.4.1.1. Brazil market, By End User, 2021 - 2030 (USD Million) 12.4.4.1.3. Brazil market, by Application, 2021 - 2030 (USD Million) 12.4.4.2. Mexico 12.4.4.2.1. Mexico market, By End User, 2021 - 2030 (USD Million) 12.4.4.2.3. Mexico market, by Application, 2021 - 2030 (USD Million) 12.4.4.3. Rest of Latin America 12.4.4.3.1. Rest of the Latin America market, By End User, 2021 - 2030 (USD Million) 12.4.4.3.3. Rest of the Latin America market, by Application, 2021 - 2030 (USD Million) 13. Competitive Landscape 13.1 Zoetis. 13.1.1. Company overview 13.1.2. Financial performance 13.1.3. Product Portfolio Analysis 13.1.4. Business Strategy & Recent Development 13.2. Elanco. 13.2.1. Company overview 13.2.2. Financial performance 13.2.3. Product Portfolio Analysis 13.2.4. Business Strategy & Recent Development 13.3. Bayer AG. 13.3.1. Company overview 13.3.2. Financial performance 13.3.3. Product Portfolio Analysis 13.3.4. Business Strategy & Recent Development 13.4. Norbrook. 13.4.1. Company overview 13.4.2. Financial performance 13.4.3. Product Portfolio Analysis 13.4.4. Business Strategy & Recent Development 13.5. Ceva 13.5.1. Company overview 13.5.2. Financial performance 13.5.3. Product Portfolio Analysis 13.5.4. Business Strategy & Recent Development 13.6. Dechra Pharmaceuticals. 13.6.1. Company overview 13.6.2. Financial performance 13.6.3. Product Portfolio Analysis 13.6.4. Business Strategy & Recent Development 13.7. Assisi Animal Health 13.7.1. Company overview 13.7.2. Financial performance 13.7.3. Product Portfolio Analysis 13.7.4. Business Strategy & Recent Development 13.8. Merck Sharp & Dohme Corp. 13.8.1. Company overview 13.8.2. Financial performance 13.8.3. Product Portfolio Analysis 13.8.4. Business Strategy & Recent Development 13.9. Boehringer Ingelheim International GmbH. 13.9.1. Company overview 13.9.2. Financial performance 13.9.3. Product Portfolio Analysis 13.9.4. Business Strategy & Recent Development 13.10. Virbac. 13.10.1. Company overview 13.10.2. Financial performance 13.10.3. Product Portfolio Analysis 13.10.4. Business Strategy & Recent Development 13.11. IDEXX Laboratories. 13.11.1. Company overview 13.11.2. Financial performance 13.11.3. Product Portfolio Analysis 13.11.4. Business Strategy & Recent Development 13.12. Vetoquinol. 13.12.1. Company overview 13.12.2. Financial performance 13.12.3. Product Portfolio Analysis 13.12.4. Business Strategy & Recent Development 13.13. Evonik Industries AG 13.13.1. Company overview 13.13.2. Financial performance 13.13.3. Product Portfolio Analysis 13.13.4. Business Strategy & Recent Development 13.14. DuPont. 13.14.1. Company overview 13.14.2. Financial performance 13.14.3. Product Portfolio Analysis 13.14.4. Business Strategy & Recent Development 13.15. DSM. 13.15.1. Company overview 13.15.2. Financial performance 13.15.3. Product Portfolio Analysis 13.15.4. Business Strategy & Recent Development 13.16. Adisseo. 13.16.1. Company overview 13.16.2. Financial performance 13.16.3. Product Portfolio Analysis 13.16.4. Business Strategy & Recent Development 13.17. ADM Nutreco 13.17.1. Company overview 13.17.2. Financial performance 13.17.3. Product Portfolio Analysis 13.17.4. Business Strategy & Recent Development 13.18. Novusint Cargill Incorporated 13.18.1. Company overview 13.18.2. Financial performance 13.18.3. Product Portfolio Analysis 13.18.4. Business Strategy & Recent Development 13.19. Charoen Pokphand Group 13.19.1. Company overview 13.19.2. Financial performance 13.19.3. Product Portfolio Analysis 13.19.4. Business Strategy & Recent Development 13.20. Sumitomo Chemical 13.20.1. Company overview 13.20.2. Financial performance 13.20.3. Product Portfolio Analysis 13.20.4. Business Strategy & Recent Development 13.21. Kemin Industries, Inc 13.21.1. Company overview 13.21.2. Financial performance 13.21.3. Product Portfolio Analysis 13.21.4. Business Strategy & Recent Development 13.22. Medtronic 13.22.1. Company overview 13.22.2. Financial performance 13.22.3. Product Portfolio Analysis 13.22.4. Business Strategy & Recent Development 13.23. BASF SE 13.23.1. Company overview 13.23.2. Financial performance 13.23.3. Product Portfolio Analysis 13.23.4. Business Strategy & Recent Development List of Tables (81 Tables) TABLE 1. MARKET, By Product, 2021-2030 (USD Million) TABLE 2. MARKET FOR NSAIDs, BY REGION, 2021-2030 (USD Million) TABLE 3. MARKET FOR Anaesthetics, BY REGION, 2021-2030 (USD Million) TABLE 4. MARKET FOR Opioids, BY REGION, 2021-2030 (USD Million) TABLE 5. MARKET FOR Other Drugs, BY REGION, 2021-2030 (USD Million) TABLE 6. MARKET, By Devices, 2021-2030 (USD Million) TABLE 7. MARKET FOR Laser Therapy, BY REGION, 2021-2030 (USD Million) TABLE 8. MARKET FOR Electromagnetic Therapy, BY REGION, 2021-2030 (USD Million) TABLE 9. MARKET FOR Optical, BY REGION, 2021-2030 (USD Million) TABLE 10. MARKET, By Animal Type Type, 2021-2030 (USD Million) TABLE 11. MARKET FOR Companion, BY REGION, 2021-2030 (USD Million) TABLE 12. MARKET FOR Livestock, BY REGION, 2021-2030 (USD Million) TABLE 13. MARKET, By End User, 2021-2030 (USD Million) TABLE 14. MARKET FOR Hospitals and Clinics, BY REGION, 2021-2030 (USD Million) TABLE 15. MARKET FOR Retail Pharmacy Outlets, BY REGION, 2021-2030 (USD Million) TABLE 16. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 17. MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 18. MARKET FOR Osteoarthritis and Joint Pain, BY REGION, 2021-2030 (USD Million) TABLE 19. MARKET FOR Postoperative Pain, BY REGION, 2021-2030 (USD Million) TABLE 20. MARKET FOR Cancer, BY REGION, 2021-2030 (USD Million) TABLE 21. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 22. MARKET, BY REGION, 2021-2030 (USD Million) TABLE 23. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 24. NORTH AMERICA MARKET, BY Applications, 2021-2030 (USD Million) TABLE 25. NORTH AMERICA MARKET, By End User, 2021-2030 (USD Million) TABLE 26. NORTH AMERICA MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 27. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 28. EUROPE MARKET, By End User, 2021-2030 (USD Million) TABLE 29. EUROPE MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 30. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 31. ASIA-PACIFIC MARKET, By End User, 2021-2030 (USD Million) TABLE 32. ASIA-PACIFIC MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 33. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 34. LAMEA MARKET, By End User, 2021-2030 (USD Million) TABLE 35. LAMEA MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 36. Zoetis: COMPANY SNAPSHOT TABLE 37. Zoetis: OPERATING SEGMENTS TABLE 38. Elanco: COMPANY SNAPSHOT TABLE 39. Elanco: OPERATING SEGMENTS TABLE 40. Bayer AG: COMPANY SNAPSHOT TABLE 41. Bayer AG: OPERATING SEGMENTS TABLE 42. Norbrook: COMPANY SNAPSHOT TABLE 43. Norbrook: OPERATING SEGMENTS TABLE 44. Ceva: COMPANY SNAPSHOT TABLE 45. Ceva: OPERATING SEGMENTS TABLE 46. Dechra Pharmaceuticals: COMPANY SNAPSHOT TABLE 47. Dechra Pharmaceuticals: OPERATING SEGMENTS TABLE 48. Assisi Animal Health: COMPANY SNAPSHOT TABLE 49. Assisi Animal Health: OPERATING SEGMENTS TABLE 50. Merck Sharp & Dohme Corp: COMPANY SNAPSHOT TABLE 51. Merck Sharp & Dohme Corp: OPERATING SEGMENTS TABLE 52. Boehringer Ingelheim International GmbH: COMPANY SNAPSHOT TABLE 53. Boehringer Ingelheim International GmbH: OPERATING SEGMENTS TABLE 54. Virbac: COMPANY SNAPSHOT TABLE 55. Virbac: OPERATING SEGMENTS TABLE 56. IDEXX Laboratories: COMPANY SNAPSHOT TABLE 57. IDEXX Laboratories: OPERATING SEGMENTS TABLE 58. Vetoquinol: COMPANY SNAPSHOT TABLE 59. Vetoquinol: OPERATING SEGMENTS TABLE 60. Evonik Industries AG: COMPANY SNAPSHOT TABLE 61. Evonik Industries AG: OPERATING SEGMENTS TABLE 62. DuPont: COMPANY SNAPSHOT TABLE 63. DuPont: OPERATING SEGMENTS TABLE 64. DSM: COMPANY SNAPSHOT TABLE 65. DSM: OPERATING SEGMENTS TABLE 66. Adisseo: COMPANY SNAPSHOT TABLE 67. Adisseo: OPERATING SEGMENTS TABLE 68. BASF SE: COMPANY SNAPSHOT TABLE 69. BASF SE: OPERATING SEGMENTS TABLE 70. ADM Nutreco : COMPANY SNAPSHOT TABLE 71. ADM Nutreco : OPERATING SEGMENTS TABLE 72. Novusint Cargill Incorporated: COMPANY SNAPSHOT TABLE 73. Novusint Cargill Incorporated: OPERATING SEGMENTS TABLE 74. Charoen Pokphand Group: COMPANY SNAPSHOT TABLE 75. Charoen Pokphand Group: OPERATING SEGMENTS TABLE 76. Sumitomo Chemical: COMPANY SNAPSHOT TABLE 77. Sumitomo Chemical: OPERATING SEGMENTS TABLE 78. Kemin Industries, Inc: COMPANY SNAPSHOT TABLE 79. Kemin Industries, Inc: OPERATING SEGMENTS TABLE 80. Medtronic: COMPANY SNAPSHOT TABLE 81. Medtronic: OPERATING SEGMENTS List of Figures (26 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Application-Based Estimation Figure 6 Top 23 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2021 Figure 8 Import Data for Veterinary Pain Management, By Country, 2016–2021 (USD Thousand) Figure 9 Export Data for Veterinary Pain Management, By Country, 2016–2021 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market, By Product, 2019 vs. 2025 (USD Million) Figure 12 Market, By Devices, 2019 vs. 2025 (USD Million) Figure 13 Market, By Animal Type, 2019 vs. 2025 (USD Million) Figure 14 Market, By End User, 2019 vs. 2025 (USD Million) Figure 15 Market Share, By Application Type, 2019 vs. 2025 Figure 16 Geographical Snapshot of the Market Figure 17 NSAIDs to Witness Higher CAGR in Market for Product Segment during Forecast Period. Figure 18 Laser Therapy to Witness Higher CAGR in Market for Devices Type Segment during Forecast Period. Figure 19 Companion to Witness Higher CAGR in Market for Animal Type Segment during Forecast Period. Figure 20 Hospitals and Clinics to Witness Higher CAGR in Market for End User Segment during Forecast Period. Figure 21 Osteoarthritis and Joint Pain to Witness Higher CAGR in Market for Application Segment during Forecast Period. Figure 22 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 23 Market: Drivers, Restraints, Opportunities, and Challenges Figure 24 North America: Market Snapshot Figure 25 Asia Pacific: Market Snapshot Figure 26 Vendor Dive: Evaluation Overview